{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"14.900","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"105,166,176","primaryexch":"香港交易所","ric":"2257.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BLBJM84","am":"5.94","iv":"","ew_strike":"","as":"14.500","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"14.460","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"50","update_time":"2025-09-28 00:06:03.0","lo52":"2.350","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"黃夢瑩","underlying_ric":"2257.HK","hi52":"22.780","issuer_name":"聖諾醫藥 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日15:59","aum_date":"","lo":"14.190","mkt_cap":"1.52","f_aum_hkd":null,"ew_sub_per_to":"","ls":"14.460","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.050","aum":"","issued_shares_class_B":null,"vo":"407.25","secondary_listing_flag":false,"listing_date":"2021年12月30日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"聖諾醫藥 - B","nm_s":"聖諾醫藥－Ｂ","sym":"2257","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Sirnaomics Ltd是一家投資控股公司。該公司及其子公司是臨床階段的生物技術公司，從事核糖核酸干擾（RNAi）技術和多種療法的開發和商業化。該公司致力於發現和開發針對該地區未滿足醫療需求的適應症的藥物。其主要臨床候選藥物包括STP705和STP707。其STP705是一種用於治療非黑色素瘤皮膚癌 (NMSC) 的無菌藥物產品，包括原位鱗狀細胞癌和基底細胞癌 (BCC)、瘢痕疙瘩切除術後復發的瘢痕疙瘩、肥厚性瘢痕 (HTS) 和實體肝腫瘤，以及 用於醫學美容。其STP707是一種無菌藥物產品，用於治療實體瘤，包括肝癌、轉移性皮膚鱗狀細胞皮膚癌 (cSCC) 和非小細胞肺癌。其正在利用其雙重交付平台，其中包括多肽納米顆粒 (PNP) 和GalAhead。","op":"14.400","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港<br/>灣仔<br/>皇后大道東183號<br/>合和中心46樓","pc":"-0.34","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"USD","hdr":false,"launch_date":"","hc":"14.510","isin":"KYG2050P1028","moneyness":""}},"qid":"1759074437459"}
